Skip to content
NAD+ Picks
← Research
Evidence

What is NMN? The molecule, the one step to NAD⁺, and what raising it buys

NMN is one enzymatic step from NAD⁺, and human trials show it reliably raises blood NAD⁺. What two systematic reviews found about everything downstream of that is a much quieter story.

Laura Bennett6 min read
NMN is one step away from NAD⁺ — not a version of itNMNone enzymeNAD⁺MEASURED· Blood NAD⁺ rises on NMN· Dose-dependent, repeatableNOT ESTABLISHED· Glucose and lipid benefit· Energy, focus, slower agingRaising a blood level is a measurement. Whether anything follows from it is a separate question.

NMN is nicotinamide mononucleotide: a small molecule built from a form of vitamin B3, a sugar and a phosphate group. In your cells it sits one enzymatic step away from NAD⁺, the coenzyme every cell in your body uses to run its metabolism. That single step is the whole reason anyone sells it.

So NMN is not NAD⁺, and it is not a weaker or cheaper version of NAD⁺. It is an input. You swallow it, your cells convert it, and the NAD⁺ you end up with is your own. The same is true of nicotinamide riboside, the other common precursor — the two differ in structure and in how much research each has behind it.

What happens when you actually take it

This part is well documented, and it is worth separating from everything that comes after, because it is the claim the evidence genuinely supports.

The first human safety study gave 10 healthy men single oral doses of 100, 250 and 500 mg and tracked them for five hours. No significant clinical symptoms, no meaningful changes in heart rate, blood pressure or oxygen saturation — and plasma concentrations of two nicotinamide breakdown products rose significantly and dose-dependently, which is how the authors established that the NMN was being absorbed and metabolized rather than passing through [1].

Longer trials measured the thing people actually care about. In a randomized, double-blind, placebo-controlled trial of 80 healthy middle-aged adults (n = 80) taking placebo, 300, 600 or 900 mg once daily for 60 days, blood NAD concentrations rose significantly in every NMN group at day 30 and day 60 against both placebo and baseline (all p ≤ 0.001), with the highest levels in the 600 and 900 mg arms [2].

That is a real, repeatable, dose-responsive result. If someone tells you NMN does not get absorbed, they are wrong.

And here is the part the marketing skips

Raising a blood level is a measurement, not a benefit. The question is what follows from it, and the honest answer is: less than you would guess from the packaging.

A systematic review pooled eight randomized human trials of NMN — doses from 250 to 2,000 mg daily, durations from 14 days to 12 weeks, 342 mostly non-diabetic middle-aged and older adults in total — and found no significant benefit on fasting glucose, fasting insulin, glycated hemoglobin, HOMA-IR or any lipid measure[3]. A larger and more recent review of 15 trials reached the same place from the safety side: NMN was well tolerated, did not raise liver enzymes or adverse events, and showed no significant effect on body weight, BMI, fasting glucose, HbA1c, lipids or systolic blood pressure [4].

Read those two sentences together and you have the state of the field. NMN reliably does the mechanistic thing. What the mechanistic thing buys a healthy person has mostly not shown up when people looked for it — a pattern that runs through the wider NAD⁺ evidence base as well.

Where something real did show up

Not nowhere. In a 10-week randomized, placebo-controlled, double-blind trial in postmenopausal women with prediabetes who were overweight or obese, NMN increased insulin-stimulated glucose disposal measured by hyperinsulinemic-euglycemic clamp — the reference method — along with skeletal muscle insulin signaling, with no change on placebo[5].

Notice the shape of that finding. A specific population with a specific metabolic problem, a specific measurement, a real effect. It is good evidence for exactly what it says, and it is not evidence that a healthy forty-year-old will feel different.

How to think about NMN before you buy any

Three things are true at once, and most pages on this topic tell you only one of them. NMN is absorbed and raises NAD⁺. The downstream benefits it is sold for are largely unproven in healthy people. And it is still, on evidence per dollar, a far better proposition than the injections and IV drips sold as NAD⁺ therapy, which have no controlled outcome trials of their own and cost several times more.

That inversion — the cheapest format carrying the best data — is the single most useful fact in this category. If you want to see it laid out by format rather than by molecule, the format finder does that, and the oral precursor ranking is where the evidence actually points. If you get as far as buying some, the bottles hold wildly different amounts, so we rank the brands by what a gram of NMN actually costs.

Frequently asked

What is NMN, in one sentence?
Nicotinamide mononucleotide — a small molecule built from a form of vitamin B3, a sugar and a phosphate group, sitting one enzymatic step away from NAD⁺, the coenzyme your cells use to run their metabolism.
Is NMN the same thing as NAD⁺?
No. NMN is an input your cells convert into NAD⁺; it is not a form of NAD⁺ and not a substitute for it. Nicotinamide riboside is the other common precursor. Comparing NMN with NAD⁺ is comparing an ingredient with the thing made from it.
Does NMN actually raise NAD⁺ in people?
Yes, and this is the best-supported claim in the category. In a randomized, double-blind, placebo-controlled trial of 80 healthy middle-aged adults taking 300, 600 or 900 mg daily for 60 days, blood NAD rose significantly in every NMN group at day 30 and day 60 against both placebo and baseline, at p ≤ 0.001.
If NMN raises NAD⁺, why do reviews say it does not work?
Because raising a blood level and producing a health benefit are different results. A systematic review of eight randomized trials covering 342 adults found no significant benefit on fasting glucose, insulin, glycated hemoglobin, HOMA-IR or lipids, and a later review of 15 trials found no significant effect on body weight, BMI, glucose, HbA1c, lipids or systolic blood pressure. The mechanism works; the downstream benefits mostly have not appeared when measured.
Has NMN ever produced a real clinical effect?
In one well-designed trial, yes. In postmenopausal women with prediabetes who were overweight or obese, 10 weeks of NMN increased insulin-stimulated glucose disposal measured by hyperinsulinemic-euglycemic clamp, with no change on placebo. That is strong evidence for that population and that outcome, and it is not evidence that a healthy adult will notice anything.

Sources

  1. [1] Irie J, Inagaki E, Fujita M, et al. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men Endocrine Journal. PMID 31685720
  2. [2] Yi L, Maier AB, Tao R, et al. (2023). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial GeroScience. PMID 36482258
  3. [3] Chen F, Zhou D, Kong AP, et al. (2024). Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials Current Diabetes Reports. PMID 39531138
  4. [4] Yang W, Huang J, Tang Z, et al. (2026). Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis Nutrients. PMID 42514320
  5. [5] Yoshino M, Yoshino J, Kayser BD, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women Science. PMID 33888596

Where to get it

Oral NAD⁺ precursors (NR and NMN)

The cheapest route with the strongest human data — and the one we earn nothing from.

Compare providers →

More in Evidence